The biotech boom

摘要

The deal capped a series of successful agreements within the Austrian biotech sector: In February of this year, British drug giant GlaxoSmithKline secured the license rights for a medicine which treats acute respiratory distress syndrome from Austrian-based Apeiron Biologies AG.